More about High-Yield Cash Accounts with M1
Brokerage Accounts
Retirement Accounts
Other Accounts
Quotes are delayed by 15 minutes.
1D
1W
1M
3M
6M
YTD
1Y
2Y
5Y
ALL
AUM
$1.72B
P/E ratio
26.4
Dividend yield
1.3452%
Expense ratio
0.37%
Beta
0.469595
Previous close
$111.03
Today's open
$111.84
Day's range
$109.43 - $112.29
52 week range
$80.25 - $112.29
Industries
Health
Pharmaceuticals ETF (IHE) Hits a New 52-Week High
For investors seeking momentum, iShares U.S. Pharmaceuticals ETF IHE is probably on the radar. The fund just hit a 52-week high and is up 42.76% from its 52-week low price of $77.52/share.
Zacks Investment Research • Nov 11, 2026

Which Is the Better Buy: iShares' Pharma ETF IHE or First Trust's Biotech Fund FBT?
iShares U.S. Pharmaceuticals ETF has a lower expense ratio than the First Trust NYSE Arca Biotechnology Index Fund. First Trust NYSE Arca Biotechnology Index Fund maintains a more concentrated portfolio.
The Motley Fool • Nov 11, 2026

ETFs in Spotlight as FDA Vision Loss Warning Meets Lilly's Sleep Apnea Win
Eli Lilly's sleep apnea breakthrough amid the FDA's vision-loss warning puts diversified healthcare ETFs in the spotlight.
Zacks Investment Research • Nov 11, 2026

How to Invest in the Rise of China's Biotech: Buy U.S. Drug Stocks
Many of the hot new drug candidates in the U.S. were developed Chinese companies.
Barrons • Nov 3, 2026

From Laggard to Leader: The Surprising Comeback of Healthcare
Healthcare stocks have finally stepped back into the spotlight. After spending much of the past several years in the shadow of technology and AI, the sector has quietly emerged as one of the year's more compelling comeback stories.
ETF Trends • Oct 13, 2026

Better Pharma ETF: iShares IHE vs. State Street XPH
The iShares U.S. Pharmaceuticals ETF is significantly more concentrated than the State Street SPDR S&P Pharmaceuticals ETF, with Eli Lilly accounting for 23.63% of the portfolio. The iShares U.S. Pharmaceuticals ETF provides a higher dividend yield of 1.4% compared to 0.4% for the State Street SPDR S&P Pharmaceuticals ETF.
The Motley Fool • Oct 10, 2026

Execution of Pharma Tariffs Brings These ETFs Into Focus
Trump's 100% pharma tariff is reshaping the drug industry. Here's how the key pharma ETFs could be affected.
Zacks Investment Research • Oct 6, 2026

Should You Invest in the iShares U.S. Pharmaceuticals ETF (IHE)?
The iShares U.S. Pharmaceuticals ETF (IHE) was launched on May 1, 2006, and is a passively managed exchange traded fund designed to offer broad exposure to the Healthcare - Pharma segment of the equity market.
Zacks Investment Research • Sep 15, 2026

IHE: Innovation Supports The Outlook, Valuation Limits Conviction
iShares U.S. Pharmaceuticals ETF offers concentrated exposure to US pharma, dominated by Johnson and Johnson (22.5%) and Eli Lilly and Company (20.5%). IHE benefits from structural growth in obesity therapies, robust drug pipelines, and demographic tailwinds but faces high concentration risk. Short-term catalysts include LLY's earnings momentum, FDA drug approvals, sector M&A activity, and potential interest rate improvements.
Seeking Alpha • Sep 11, 2026

IHE: Large-Cap Pharma Cools After A Hot Summer
I issue a hold rating on the iShares US Pharmaceuticals ETF due to fair valuation and mounting near-term headwinds. IHE's portfolio is highly concentrated, with 43% in JNJ and LLY and top 10 holdings totaling 76%. Technical trends have turned concerning, with a recent breach of trendline support and a possible 10% correction to $97 likely through October.
Seeking Alpha • Sep 10, 2026

¹ Disclosures

Open an M1 investment account to buy and sell iShares U.S. Pharmaceuticals ETF commission-free¹. Build wealth for the long term using automated trading and transfers.